NASDAQ:ALPN
Alpine Immune Sciences Inc Stock News
$64.56
-0.0600 (-0.0929%)
At Close: Apr 26, 2024
3 Biotech Stocks That Jumped Higher Last Week
06:43am, Sunday, 23'rd May 2021
Find out what pushed them up to see if the good times can keep rolling.
Alpine Immune Sciences, Inc. (ALPN) Moves 9.5% Higher: Will This Strength Last?
06:01am, Thursday, 20'th May 2021
Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there coul
Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting
05:10pm, Wednesday, 19'th May 2021
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Lags Revenue Estimates
07:41pm, Thursday, 13'th May 2021
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -40.63% and -45.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for th
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
03:46pm, Thursday, 06'th May 2021
Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Alpine (ALPN) Stock?
09:04am, Friday, 16'th Apr 2021
Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.
Alpine Immune Sciences Is A Blind Buy After The Recent Price Decrease
05:28pm, Thursday, 15'th Apr 2021
The strategic agreement with AbbVie for the development of ALPN-101 is the most valuable asset of the company. The recent share price decline can be attributed to several factors, including the expect
Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q4 2020 Results - Earnings Call Transcript
10:32pm, Thursday, 18'th Mar 2021
Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q4 2020 Results - Earnings Call Transcript
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Tops Revenue Estimates
06:33pm, Thursday, 18'th Mar 2021
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 0.00% and 101.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for t
Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I
04:30pm, Wednesday, 10'th Mar 2021
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I
7 Micro-Cap Stocks That Are Worth the Risk
09:05am, Thursday, 07'th Jan 2021
Although micro-cap stocks don't perform well during an economic downturn, they outperform the market during periods of recovery. Here are 7 stocks to invest in as we head toward a new normal.
Alpine: Is This A Young Oak Tree?
01:22pm, Tuesday, 05'th Jan 2021
Alpine Immune Sciences is a stellar growth bio-stock that is reaching a point of growth inflection. Back in June last year, Alpine secured a highly favorable partnership with AbbVie.
These 4 Micro-Cap Healthcare Stocks Gained the Most in 2020
07:04am, Friday, 01'st Jan 2021
Innovation paid off big for investors.
Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
08:00am, Friday, 11'th Dec 2020
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q3 2020 Results - Earnings Call Transcript
07:24pm, Thursday, 12'th Nov 2020
Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q3 2020 Results - Earnings Call Transcript
